WAB 90.22 Wabtec Corp $WAB Hit a 52 week high of 90.39

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:07 PM

WAB 90.22 Wabtec Corp $WAB Hit a 52 week high of 90.39 Currently at 90.22 +0.95 +1.06% With a day low of 89.66 and a total volume of 58,966.

WAB Wabtec Corp Recent Headline News

Stocks Higher At Midday; Motorcar Clears Buy Point
at Investor's Business Daily - 2 hrs 11 mins ago
The major averages were higher at midday Monday, led by transportation stocks. The Nasdaq rose 0.4%, the S&P 500 added 0.3% and the Dow Jones industrial average edged up 0.2%. Volume was quiet in the stock market today, down 6% on the NYSE and 3%...
SWIR: 35.86 (+1.96), CSTE: 60.23 (-1.35), MPAA: 31.13 (+1.86), WAB: 89.65 (+0.38)

Earnings Look Back: Wabtec Is Up 8.2% Since Reporting Quarterly Results 1 Week Ago (WAB)
Comtex SmarTrend(R) - Mon Nov 10, 8:14AM CST
13 days ago, on October 28th, 2014, Wabtec (NYSE:WAB) reported its earnings. Analysts, on average, expected earnings of $0.89 per share on sales of $750.1 million. The company actually reported EPS of $0.93 on sales of $797.3 million, beating EPS estimates by $0.04 and beating revenue estimates by $47.2 million. Shares of Wabtec have climbed from $82.49 to $89.27, representing a gain of 8.2% since the company reported earnings 13 days ago.
WAB: 89.65 (+0.38)

Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 31.80 (-0.08), RGLS: 22.61 (+0.53), WAB: 89.65 (+0.38)

Uptrend Call Working As Wabtec Stock Rises 12.0% (WAB)
Comtex SmarTrend(R) - Thu Nov 06, 10:05AM CST
SmarTrend identified an Uptrend for Wabtec (NYSE:WAB) on October 22nd, 2014 at $77.38. In approximately 2 weeks, Wabtec has returned 11.99% as of today's recent price of $86.65.
WAB: 89.65 (+0.38)

Westinghouse profit on track
at Investor's Business Daily - Tue Oct 28, 5:46PM CDT
The maker of equipment for locomotives and other vehicles said that its Q3 EPS climbed 22% to 93 cents, beating by 4 cents a share. Revenue grew 26.3% to $797.3 mil vs. consensus for $750.3 mil. It was the 4th quarter in a row that Westinghouse Air...
WAB: 89.65 (+0.38)

Wabtec beats 3Q profit forecasts
Automated Insights - Tue Oct 28, 7:01AM CDT
WILMERDING, Pa. (AP) _ Westinghouse Air Brake Technologies Corp. (WAB) on Tuesday reported earnings of $90.2 million in its third quarter.
WAB: 89.65 (+0.38)

Wabtec Reports Record Quarterly Results; 3Q EPS of 93 Cents, Up 22 Percent; Increases Full-Year EPS Guidance
PR Newswire - Tue Oct 28, 6:49AM CDT
Wabtec Corporation (NYSE: WAB) today reported record results for the 2014 third quarter, including the following:
WAB: 89.65 (+0.38)

Wabtec announces dividend of USD0.06 per share for quarter
M2 - Thu Oct 16, 4:02AM CDT
Wabtec Corporation (NYSE:WAB), a provider of value-added, technology-based rail and transit products and services, reported on Wednesday its regular quarterly dividend of USD0.06 per share.
WAB: 89.65 (+0.38)

Wabtec Declares Regular Quarterly Dividend, Announces Earnings Release Date
PR Newswire - Wed Oct 15, 7:55AM CDT
Wabtec Corporation (NYSE: WAB) declared its regular quarterly dividend of 6 cents per share, payable on Nov. 28, 2014 to holders of record on Nov. 14, 2014.
WAB: 89.65 (+0.38)

Stocks Sell Off Amid Europe Woes, Mixed U.S. Data
at Investor's Business Daily - Wed Oct 01, 3:25PM CDT
Stocks sold off hard Wednesday, sparked by concerns about economic weakness in Europe and mixed U.S. economic data. The Nasdaq plunged 1.6%, while the Dow industrials sank 1.4% and the S&P 500 lost 1.3%. Volume rose across the board in the stock...
AYI: 140.02 (-0.37), ARII: 68.92 (+2.64), SWKS: 61.05 (+1.17), GBX: 61.92 (+2.01), TRN: 35.84 (+0.14), RGLD: 62.47 (-2.95), WAB: 89.65 (+0.38)

Greenbrier, Trinity Dive On Oil Tank Car Rule Fight
at Investor's Business Daily - Wed Oct 01, 12:08PM CDT
Greenbrier and other rail car makers sold off hard Wednesday after oil and railroad industry trade groups asked for more time to retrofit old cars to transport extremely flammable crude from tar sand plays. The American Petroleum Institute and the...
GBX: 61.92 (+2.01), TRN: 35.84 (+0.14), RAIL: 34.06 (+0.70), WAB: 89.65 (+0.38)

Wabtec Up 10.7% Since SmarTrend Uptrend Call (WAB)
Comtex SmarTrend(R) - Thu Sep 18, 4:57PM CDT
SmarTrend identified an Uptrend for Wabtec (NYSE:WAB) on April 23rd, 2014 at $75.62. In approximately 5 months, Wabtec has returned 10.69% as of today's recent price of $83.70.
WAB: 89.65 (+0.38)

Rail Transport Equipment: Let Growth Light the Way - Zacks Industry Rank Analysis
John Blank - Zacks Investment Research - Thu Sep 18, 12:43AM CDT
Rail Transport Equipment: Let Growth Light the Way - Zacks Industry Rank Analysis
GBX: 61.92 (+2.01), TRN: 35.84 (+0.14), WAB: 89.65 (+0.38), UNP: 120.95 (+2.20)

Market Indexes Rally Ahead Of Fed Statement
at Investor's Business Daily - Tue Sep 16, 3:30PM CDT
Stocks shrugged off early weakness and extended their gains through the session to close near session highs ahead of Wednesday's Federal Reserve statement. The Nasdaq and S&P 500 each closed up nearly 0.8%, while the Dow industrials, which hit a new...
TSLA: 241.37 (+1.17), ARII: 68.92 (+2.64), CNW: 46.13 (+0.70), GBX: 61.92 (+2.01), TRN: 35.84 (+0.14), WAB: 89.65 (+0.38)

9.8% Return Seen to Date on SmarTrend Wabtec Call (WAB)
Comtex SmarTrend(R) - Wed Sep 10, 5:22PM CDT
SmarTrend identified an Uptrend for Wabtec (NYSE:WAB) on April 23rd, 2014 at $75.62. In approximately 5 months, Wabtec has returned 9.77% as of today's recent price of $83.00.
WAB: 89.65 (+0.38)

Greenbrier's Stock Chart Is Showing Positives
at Investor's Business Daily - Tue Sep 09, 5:16PM CDT
Greenbrier Cos. (GBX) is extended from a rebound off its 10-week moving average and a long price run since late October, but it bears watching for a potential base down the line. Despite not being in a buying area, Greenbrier is showing some positive...
GBX: 61.92 (+2.01), TRN: 35.84 (+0.14), WAB: 89.65 (+0.38)

Wabtec Shares Up 11.2% Since SmarTrend's Buy Recommendation (WAB)
Comtex SmarTrend(R) - Wed Sep 03, 5:27PM CDT
SmarTrend identified an Uptrend for Wabtec (NYSE:WAB) on April 23rd, 2014 at $75.62. In approximately 4 months, Wabtec has returned 11.23% as of today's recent price of $84.11.
WAB: 89.65 (+0.38)

Wabtec Acquires C2CE, A Leading Provider of Railway Signal Design Services in Australia
PR Newswire - Wed Sep 03, 7:00AM CDT
Wabtec Corporation (NYSE: WAB) has acquired C2CE Pty Ltd., a leading provider of railway signal design services in Australia. Based in Perth, Australia, C2CE has annual sales of about $35 million.
WAB: 89.65 (+0.38)

11.7% Return Seen to Date on SmarTrend Wabtec Call (WAB)
Comtex SmarTrend(R) - Tue Aug 26, 9:48AM CDT
SmarTrend identified an Uptrend for Wabtec (NYSE:WAB) on April 23rd, 2014 at $75.62. In approximately 4 months, Wabtec has returned 11.67% as of today's recent price of $84.44.
WAB: 89.65 (+0.38)

Wabtec Acquires Dia-Frag, A Leading Manufacturer of Friction Products in Brazil
PR Newswire - Thu Aug 21, 7:01AM CDT
Wabtec Corporation (NYSE: WAB) has acquired Dia-Frag, a leading manufacturer of friction products in Brazil. Based in Monte Alto, Brazil, Dia-Frag has annual sales of about $40 million.
WAB: 89.65 (+0.38)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Hits Legal Snag: Investors Called to Act

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Sinclair Faces Labor Lawsuit for Break-time Violations

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Spooky Dining at CARNE: A Halloween Hit in Oxnard

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...